Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting
Rona Yaeger, David B. Solit
Abstract
Abstract KRAS G12C inhibitors have shown promise in KRAS G12C–mutant lung cancer but intrinsic and acquired resistance are common. Cotreatment with inhibitors of the protein phosphatase SHP2 can abrogate the adaptive response of cancer cells to KRAS inhibitors resulting in greater suppression of MAPK signaling and enhanced tumor growth inhibition. See related article by Ryan et al., p. 1633
Topics & Concepts
KRASAcquired resistanceCancer researchMAPK/ERK pathwayCancerPhosphataseSignal transductionLung cancerCancer cellBiologyMedicinePhosphorylationCell biologyInternal medicineColorectal cancerGeneticsProtein Tyrosine PhosphatasesMelanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling